ARID1B and non-small cell lung carcinoma: Similarly, another study observed that NSCLC patients who had ctDNA detectable AT-rich interacting domain containing protein 1A gene (ARID1A) mutations or AT-rich interacting domain-containing protein 1B gene (ARID1B) mutations had a beneficial response to anti PD-(L)1 IO and a prolonged PFS [72].